Changes in the income-tax, likely good monsoon and the on-going above normal Rabi acreage along with higher MSPs are the key triggers analysts are betting on for the consumption revival
Home-grown FMCG major Dabur India is looking at the future with "great optimism" but challenges from the pandemic are far from over, its Vice Chairman Mohit Burman said
The management is confident of double digit sales growth and steady margins in FY22
The firm reported a 28.4 per cent jump in its profit after tax (PAT) on a year-on-year basis
Dabur India's healthcare products are set to witness strong performance over the medium-term as customers focus on immunity booster and healthy lifestyle
The firm has secured 51 acres of land and begun construction work for the initial phase, which is to be completed within the current financial year
M-cap of top 10 firms has risen 12% in 1 year, against 42% rally in Nifty50
The 14-period RSI has seen positive crossover affirming the bullish stance in the Dabur counter from a short to medium-term perspective
The maker of honey, chyawanprash, oils and juices had reported a net profit of Rs 281.6 crore last year
In the past one month, the stock rallied 8 per cent, against 4 per cent decline in the S&P BSE Sensex
Companies are also looking for change in product mix and cost saving measures
The rate rejig, analysts say, will alter the tax burden on companies, which they expect to get passed on to the consumers
A media report said Dabur promoter would sell 0.5 per cent equity stake to raise Rs 460 crore at Rs 509.65-520.05 per share
OTC drugs, health supplements and immunity boosting products grow in healthy double digits
The firm was helped by the expansion of the distribution network and consumer centric innovations
For many businesses, the need to have people coming into office has shrunk. For many others, however, it remains integral to their operations
The success of Burger King at the bourses has off-late reinforced belief in the sector, especially quick service restaurants (QSRs), provided the stocks are attractively valued
India is likely to issue an emergency use authorisation to at least one Covid vaccine by the end of January and health workers will be the first to be inoculated. More headlines in our evening roundup
The stock has rallied 5% in two trading days, quoting close to its 52-week high level of Rs 535 touched on October 6, 2020
Domestic sales drive the numbers as operating revenue grows 14%